ESSA Pharma (NASDAQ:EPIX – Get Free Report) (TSE:EPI) posted its quarterly earnings data on Monday. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.10, Zacks reports.
ESSA Pharma Price Performance
Shares of NASDAQ:EPIX traded up $0.09 during mid-day trading on Wednesday, hitting $4.55. The company had a trading volume of 21,321 shares, compared to its average volume of 95,078. ESSA Pharma has a one year low of $2.58 and a one year high of $11.67. The firm has a fifty day moving average price of $5.26 and a 200 day moving average price of $7.05. The company has a market capitalization of $201.85 million, a PE ratio of -7.60 and a beta of 1.82.
Wall Street Analyst Weigh In
Separately, Oppenheimer reissued an “outperform” rating and issued a $17.00 price objective on shares of ESSA Pharma in a research note on Thursday, May 16th.
About ESSA Pharma
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Further Reading
- Five stocks we like better than ESSA Pharma
- How to Choose Top Rated Stocks
- What Are Bonds? A High-Level Overview
- How Technical Indicators Can Help You Find Oversold Stocks
- Super Micro Stock Drops Sharply After Earnings on Margin Concerns
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Lyft’s First-Ever Profit, but the Outlook Is a Speed Bump
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
